Blog

  • Lord Taylor of Warwick – 2015 Parliamentary Question to the Department for Business, Innovation and Skills

    Lord Taylor of Warwick – 2015 Parliamentary Question to the Department for Business, Innovation and Skills

    The below Parliamentary question was asked by Lord Taylor of Warwick on 2015-11-30.

    To ask Her Majesty’s Government what plans they have to commission a review into the obstacles that prevent more people from black and minority ethnic backgrounds from reaching senior positions in business, similar to the Women on Boards review by Lord Davies of Abersoch.

    Baroness Neville-Rolfe

    Government believes that businesses benefit from a rich and wide talent pool including people from black and minority ethnic backgrounds.

    Government is fully supportive of the private led Diversity initiative chaired by Sir John Parker who are currently considering this issue. We expect the group to report on their findings in 2016.

    There are no current plans for Government to commission a separate review into the obstacles that are preventing more people from black and minority ethnic backgrounds from reaching senior positions in the boardroom.

  • Lord Scriven – 2015 Parliamentary Question to the Department of Health

    Lord Scriven – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Scriven on 2015-11-30.

    To ask Her Majesty’s Government when it was decided that the Chief Executive of NHS England could appear on political debate shows such as Any Questions?, and who made that decision.

    Lord Prior of Brampton

    NHS England is an independent body established by the Health and Social Care Act 2012. Its Chief Executive, Simon Stevens, decided to accept the invitation to appear on the ‘Any Questions?’ programme several months ago.

  • Baroness Redfern – 2015 Parliamentary Question to the Department for Business, Innovation and Skills

    Baroness Redfern – 2015 Parliamentary Question to the Department for Business, Innovation and Skills

    The below Parliamentary question was asked by Baroness Redfern on 2015-11-30.

    To ask Her Majesty’s Government how many engineering and manufacturing apprenticeships were created in the last Parliament (1) nationally, and (2) in North Lincolnshire, and how many they are intending to create during this Parliament.

    Baroness Neville-Rolfe

    There have been 324,800 apprenticeship starts in the manufacturing technologies sector subject area nationally in the last parliament (May 2010 to April 2015).

    In North Lincolnshire Local Authority there have been 1,500 apprenticeship starts in the manufacturing technologies sector subject area in the last parliament (May 2010 to April 2015).

    We are committed to reaching 3 million apprenticeship starts in England by 2020.

    The locations and sectors where apprenticeships are available are determined by employers choosing to offer apprenticeships and recruit apprentices. We have therefore set no specific regional targets.

  • Baroness Redfern – 2015 Parliamentary Question to the Department for Communities and Local Government

    Baroness Redfern – 2015 Parliamentary Question to the Department for Communities and Local Government

    The below Parliamentary question was asked by Baroness Redfern on 2015-11-30.

    To ask Her Majesty’s Government what assessment they have made of the number of job opportunities created so far by Enterprise Zones, including how many of those opportunities are full-time, part-time, work experience or apprenticeship opportunities, both within each zone and in the surrounding area.

    Baroness Williams of Trafford

    The job opportunities which Enterprise Zones have attracted are published quarterly on a national and regional performance basis. The most recently published data covers the period up until the end of June 2015 and shows that the 24 Enterprise Zones established since 2012 have already attracted 20,676 jobs and that this number had increased by 9 per cent between March and June 2015.

    Information on the type of jobs or the number of jobs within individual zones or surrounding areas is not available.

  • Baroness Redfern – 2015 Parliamentary Question to the Department for Education

    Baroness Redfern – 2015 Parliamentary Question to the Department for Education

    The below Parliamentary question was asked by Baroness Redfern on 2015-11-30.

    To ask Her Majesty’s Government what measures University Technical Colleges are taking to increase choices for students, especially with regard to strengthening academic study with practical learning.

    Lord Nash

    University Technical Colleges (UTCs) specialise in subjects that need modern, technical, industry-standard equipment, such as engineering and digital technologies. Pupils integrate academic study with practical learning, studying core GCSEs within a high-quality technical and professional curriculum. UTCs work with local and national employers and higher education institutions to design and deliver a curriculum that, through technical projects and work experience, will provide pupils with the skills employers demand for their industries. The importance of involving employers in education is a key part of the government’s recently announced plans for ground-breaking reforms to technical and professional education.

  • Lord Lexden – 2015 Parliamentary Question to the Department for Education

    Lord Lexden – 2015 Parliamentary Question to the Department for Education

    The below Parliamentary question was asked by Lord Lexden on 2015-11-30.

    To ask Her Majesty’s Government what is their latest assessment of the extent of homophobic bullying in schools.

    Lord Nash

    All forms of bullying, including homophobic bullying, are completely unacceptable. In order to tackle homophobic bullying in schools we are providing £2 million this financial year to fund projects designed to build schools’ knowledge and capacity to prevent and tackle homophobic, biphobic and transphobic bullying in schools.

    While evidence points to a high level of lesbian, gay, bisexual and transgender young people being subjected to bullying, it also indicates that thanks to the efforts of teachers and charities it is falling. Research undertaken by Stonewall shows that homophobic bullying has reduced in recent years – 55% of Lesbian, Gay and Bisexual secondary school pupils reported experiencing homophobic bullying at school in 2012, a drop from 65% in 2007 (Stonewall School Report, 2007 and 2012). The Stonewall Report of 2014 also indicated that homophobic bullying has fallen. The number of secondary school teachers who said their pupils are often or very often the victim of homophobic bullying had almost halved, from 25 per cent in 2009 to 13 per cent in 2014 (Stonewall Teacher Report, 2014 and 2009).

  • Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2015-11-30.

    To ask Her Majesty’s Government what is the average turnaround time for cancer genetic tests relating to (1) breast cancer, (2) lung cancer, (3) colorectal cancer, and (4) melanoma, measured from biopsy to a discussion of the results with the patient, in (a) tertiary care centres, (b) secondary care centres with in-house testing, and (c) secondary care centres with third-party testing.

    Lord Prior of Brampton

    NHS England has not, to date, undertaken a direct comparison of the English and French health systems in respect of genetic testing practice for cancer.

    NHS England does not hold data on the percentage of stage 2b, or higher, cancer patients in secondary and tertiary centres who were genetically tested. Detailed information on the clinical circumstances, or reasons, for referral for genetic testing for individual patients is not currently collated on a national basis.

    NHS England does not consider business cases from individual National Health Service trusts in relation to the adoption of new genetic tests. Instead, NHS England considers national clinical commissioning policy proposals on the eligibility of a particular test, or treatments to be made available in the presence of particular genetic markers. These are considered and where agreed, funded consistently across England for services falling within NHS England’s direct commissioning responsibilities.

    Examples include the separate policies (published in July 2015) confirming eligibility for Ivacaftor for the treatment of cystic fibrosis in the presence of certain gene mutations, and confirming eligibility for testing for BRCA1 and BRCA2 gene mutations, respectively. Copies of the policies are attached.

    In addition, the UK Genetic Testing Network currently presents new genetic testing proposals to NHS England for funding consideration based on the conclusions of their assurance programme. These are considered, alongside other new policy proposals, as part of the annual funding prioritisation process, where there is a net annual investment to be made to support their adoption.

    Information on the average turnaround time for cancer genetic tests is not currently collated, or analysed, nationally. However, NHS England will be undertaking a procurement exercise in the coming months to support the strengthened provision of genetic testing across England. This includes more consistent reporting of activity and other performance indicators, including the timeliness of reporting on receipt on referrals. The supporting national service specification, setting out the standards required of commissioned providers, has been the subject of a recent public consultation.

  • Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2015-11-30.

    To ask Her Majesty’s Government how many business cases were created in NHS England trusts in 2014 that related to the business justification for introducing new tumour genetic tests; when reviewing those business cases, what percentage of trusts allowed drugs budget savings to be included, given that such savings occur outside the underlying NHS tariff; and what is their estimate of the staff hours and costs associated with creating and reviewing such business cases every year in England.

    Lord Prior of Brampton

    NHS England has not, to date, undertaken a direct comparison of the English and French health systems in respect of genetic testing practice for cancer.

    NHS England does not hold data on the percentage of stage 2b, or higher, cancer patients in secondary and tertiary centres who were genetically tested. Detailed information on the clinical circumstances, or reasons, for referral for genetic testing for individual patients is not currently collated on a national basis.

    NHS England does not consider business cases from individual National Health Service trusts in relation to the adoption of new genetic tests. Instead, NHS England considers national clinical commissioning policy proposals on the eligibility of a particular test, or treatments to be made available in the presence of particular genetic markers. These are considered and where agreed, funded consistently across England for services falling within NHS England’s direct commissioning responsibilities.

    Examples include the separate policies (published in July 2015) confirming eligibility for Ivacaftor for the treatment of cystic fibrosis in the presence of certain gene mutations, and confirming eligibility for testing for BRCA1 and BRCA2 gene mutations, respectively. Copies of the policies are attached.

    In addition, the UK Genetic Testing Network currently presents new genetic testing proposals to NHS England for funding consideration based on the conclusions of their assurance programme. These are considered, alongside other new policy proposals, as part of the annual funding prioritisation process, where there is a net annual investment to be made to support their adoption.

    Information on the average turnaround time for cancer genetic tests is not currently collated, or analysed, nationally. However, NHS England will be undertaking a procurement exercise in the coming months to support the strengthened provision of genetic testing across England. This includes more consistent reporting of activity and other performance indicators, including the timeliness of reporting on receipt on referrals. The supporting national service specification, setting out the standards required of commissioned providers, has been the subject of a recent public consultation.

  • Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2015-11-30.

    To ask Her Majesty’s Government what percentage of stage 2b cancer or higher patients in (1) tertiary, and (2) secondary, care centres were tested by NHS England in 2014 for genetic mutations that can confer resistance to targeted cancer therapies, in particular (a) AR amplification mutations, (b) ESR1 activation mutations, (c) PIK3CA mutations, (d) KRAS activation mutations, (e) EGFR amplification and activation mutations, (f) KRAS activation mutations, and (g) EGFR amplification and activation mutations.

    Lord Prior of Brampton

    NHS England has not, to date, undertaken a direct comparison of the English and French health systems in respect of genetic testing practice for cancer.

    NHS England does not hold data on the percentage of stage 2b, or higher, cancer patients in secondary and tertiary centres who were genetically tested. Detailed information on the clinical circumstances, or reasons, for referral for genetic testing for individual patients is not currently collated on a national basis.

    NHS England does not consider business cases from individual National Health Service trusts in relation to the adoption of new genetic tests. Instead, NHS England considers national clinical commissioning policy proposals on the eligibility of a particular test, or treatments to be made available in the presence of particular genetic markers. These are considered and where agreed, funded consistently across England for services falling within NHS England’s direct commissioning responsibilities.

    Examples include the separate policies (published in July 2015) confirming eligibility for Ivacaftor for the treatment of cystic fibrosis in the presence of certain gene mutations, and confirming eligibility for testing for BRCA1 and BRCA2 gene mutations, respectively. Copies of the policies are attached.

    In addition, the UK Genetic Testing Network currently presents new genetic testing proposals to NHS England for funding consideration based on the conclusions of their assurance programme. These are considered, alongside other new policy proposals, as part of the annual funding prioritisation process, where there is a net annual investment to be made to support their adoption.

    Information on the average turnaround time for cancer genetic tests is not currently collated, or analysed, nationally. However, NHS England will be undertaking a procurement exercise in the coming months to support the strengthened provision of genetic testing across England. This includes more consistent reporting of activity and other performance indicators, including the timeliness of reporting on receipt on referrals. The supporting national service specification, setting out the standards required of commissioned providers, has been the subject of a recent public consultation.

  • Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2015-11-30.

    To ask Her Majesty’s Government what assessment they have made of the performance of the NHS England cancer genetic testing service compared to the French system run by the Institute Nationale du Cancer in terms of equality of access as measured by the percentage of eligible patients who actually receive tests for (1) breast cancer, (2) lung cancer, (3) colorectal cancer, and (4) melanoma.

    Lord Prior of Brampton

    NHS England has not, to date, undertaken a direct comparison of the English and French health systems in respect of genetic testing practice for cancer.

    NHS England does not hold data on the percentage of stage 2b, or higher, cancer patients in secondary and tertiary centres who were genetically tested. Detailed information on the clinical circumstances, or reasons, for referral for genetic testing for individual patients is not currently collated on a national basis.

    NHS England does not consider business cases from individual National Health Service trusts in relation to the adoption of new genetic tests. Instead, NHS England considers national clinical commissioning policy proposals on the eligibility of a particular test, or treatments to be made available in the presence of particular genetic markers. These are considered and where agreed, funded consistently across England for services falling within NHS England’s direct commissioning responsibilities.

    Examples include the separate policies (published in July 2015) confirming eligibility for Ivacaftor for the treatment of cystic fibrosis in the presence of certain gene mutations, and confirming eligibility for testing for BRCA1 and BRCA2 gene mutations, respectively. Copies of the policies are attached.

    In addition, the UK Genetic Testing Network currently presents new genetic testing proposals to NHS England for funding consideration based on the conclusions of their assurance programme. These are considered, alongside other new policy proposals, as part of the annual funding prioritisation process, where there is a net annual investment to be made to support their adoption.

    Information on the average turnaround time for cancer genetic tests is not currently collated, or analysed, nationally. However, NHS England will be undertaking a procurement exercise in the coming months to support the strengthened provision of genetic testing across England. This includes more consistent reporting of activity and other performance indicators, including the timeliness of reporting on receipt on referrals. The supporting national service specification, setting out the standards required of commissioned providers, has been the subject of a recent public consultation.